{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:28:28Z","timestamp":1789522108410,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41375-019-0441-9","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T23:21:44Z","timestamp":1552692104000},"page":"2379-2392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5632-7833","authenticated-orcid":false,"given":"Ramin","family":"Radpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7512-513X","authenticated-orcid":false,"given":"Carsten","family":"Riether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Simillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"H\u00f6pner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Bruggmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Ochsenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"441_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894\u2013907.","journal-title":"Lancet"},{"key":"441_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA. The complexity of NF-\u03baB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.","journal-title":"Mol Cancer"},{"key":"441_CR3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ccr.2012.10.017","volume":"22","author":"BB Zeisig","year":"2012","unstructured":"Zeisig BB, Kulasekararaj AG, Mufti GJ, So CW. SnapShot: acute myeloid leukemia. Cancer Cell. 2012;22:698.","journal-title":"Cancer Cell"},{"key":"441_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138.","journal-title":"Nature"},{"key":"441_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ni1080","volume":"5","author":"KJ Hope","year":"2004","unstructured":"Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5:738\u201343.","journal-title":"Nat Immunol"},{"key":"441_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/stem.1597","volume":"32","author":"ML Guzman","year":"2014","unstructured":"Guzman ML, Allan JN. Concise review: leukemia stem cells in personalized medicine. Stem Cells. 2014;32:844\u201351.","journal-title":"Stem Cells"},{"key":"441_CR7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1535-7163.MCT-16-0889","volume":"16","author":"M Murone","year":"2017","unstructured":"Murone M, Radpour R, Attinger A, Chessex AV, Huguenin AL, Schurch CM, et al. The multi-kinase inhibitor Debio 0617B reduces maintenance and self-renewal of primary human AML CD34(+) stem\/progenitor cells. Mol Cancer Ther. 2017;16:1497\u2013510.","journal-title":"Mol Cancer Ther"},{"key":"441_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4252\/wjsc.v10.i11.160","volume":"10","author":"R Radpour","year":"2018","unstructured":"Radpour R, Forouharkhou F. Single-cell analysis of tumors: creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells. World J Stem Cells. 2018;10:160\u201371.","journal-title":"World J Stem Cells"},{"key":"441_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","volume":"91","author":"KN Rice","year":"2010","unstructured":"Rice KN, Jamieson CH. Molecular pathways to CML stem cells. Int J Hematol. 2010;91:748\u201352.","journal-title":"Int J Hematol"},{"key":"441_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1385\/SCR:1:3:181","volume":"1","author":"E Passegue","year":"2005","unstructured":"Passegue E, Weisman IL. Leukemic stem cells: where do they come from? Stem Cell Rev. 2005;1:181\u20138.","journal-title":"Stem Cell Rev"},{"key":"441_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4252\/wjsc.v9.i10.169","volume":"9","author":"R Radpour","year":"2017","unstructured":"Radpour R. Tracing and targeting cancer stem cells: new venture for personalized molecular cancer therapy. World J Stem Cells. 2017;9:169\u201378.","journal-title":"World J Stem Cells"},{"issue":"9","key":"441_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/cancers8090078","volume":"8","author":"Frank Staal","year":"2016","unstructured":"Staal FJ, Famili F, Garcia Perez L, Pike-Overzet K. Aberrant Wnt signaling in leukemia. Cancers. 2016;8:78.","journal-title":"Cancers"},{"key":"441_CR13","first-page":"6259","volume":"34","author":"S Tohda","year":"2014","unstructured":"Tohda S. NOTCH signaling roles in acute myeloid leukemia cell growth and interaction with other stemness-related signals. Anticancer Res. 2014;34:6259\u201364.","journal-title":"Anticancer Res"},{"key":"441_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00018-016-2306-y","volume":"74","author":"A Sanchez-Aguilera","year":"2017","unstructured":"Sanchez-Aguilera A, Mendez-Ferrer S. The hematopoietic stem-cell niche in health and leukemia. Cell Mol Life Sci. 2017;74:579\u201390.","journal-title":"Cell Mol Life Sci"},{"key":"441_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/stem.2761","volume":"36","author":"B Doron","year":"2018","unstructured":"Doron B, Handu M, Kurre P. Concise review: adaptation of the bone marrow stroma in hematopoietic malignancies: current concepts and models. Stem Cells. 2018;36:304\u201312.","journal-title":"Stem Cells"},{"key":"441_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/cdd.2014.89","volume":"22","author":"C Riether","year":"2015","unstructured":"Riether C, Schurch CM, Ochsenbein AF. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22:187\u201398.","journal-title":"Cell Death Differ"},{"key":"441_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2008.48","volume":"22","author":"Y Shiozawa","year":"2008","unstructured":"Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22:941\u201350.","journal-title":"Leukemia"},{"key":"441_CR18","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.3324\/haematol.2017.169516","volume":"103","author":"S Geerman","year":"2018","unstructured":"Geerman S, Brasser G, Bhushal S, Salerno F, Kragten NA, Hoogenboezem M, et al. Memory CD8(+) T cells support the maintenance of hematopoietic stem cells in the bone marrow. Haematologica. 2018;103:e230\u20133.","journal-title":"Haematologica"},{"key":"441_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1074-7613(00)80133-8","volume":"11","author":"KL Gandy","year":"1999","unstructured":"Gandy KL, Domen J, Aguila H, Weissman IL. CD8+TCR+ and CD8+TCR\u2212 cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999;11:579\u201390.","journal-title":"Immunity"},{"key":"441_CR20","first-page":"597","volume":"13","author":"G Hale","year":"1994","unstructured":"Hale G, Waldmann H. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant. 1994;13:597\u2013611.","journal-title":"Bone Marrow Transplant"},{"key":"441_CR21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129:2395\u2013407.","journal-title":"Blood"},{"key":"441_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","volume":"103","author":"R Austin","year":"2016","unstructured":"Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol. 2016;103:62\u201377.","journal-title":"Crit Rev Oncol Hematol"},{"key":"441_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-3-319-53156-4_4","volume":"995","author":"L Masarova","year":"2017","unstructured":"Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the immune system against leukemia: monoclonal antibodies and checkpoint strategies for AML. Adv Exp Med Biol. 2017;995:73\u201395.","journal-title":"Adv Exp Med Biol"},{"key":"441_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.20152008","volume":"214","author":"C Riether","year":"2017","unstructured":"Riether C, Schurch CM, Buhrer ED, Hinterbrandner M, Huguenin AL, Hoepner S, et al. CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214:359\u201380.","journal-title":"J Exp Med"},{"key":"441_CR25","doi-asserted-by":"publisher","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","volume":"7","author":"C Riether","year":"2015","unstructured":"Riether C, Schurch CM, Flury C, Hinterbrandner M, Druck L, Huguenin AL, et al. Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Sci Transl Med. 2015;7:298ra119.","journal-title":"Sci Transl Med"},{"key":"441_CR26","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252\u20139.","journal-title":"Clin Cancer Res"},{"key":"441_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3324\/haematol.13299","volume":"94","author":"RG Verhaak","year":"2009","unstructured":"Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94:131\u20134.","journal-title":"Haematologica"},{"key":"441_CR28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood-2010-03-270991","volume":"116","author":"HJ Jonge de","year":"2010","unstructured":"de Jonge HJ, Valk PJ, Veeger NJ, ter Elst A, den Boer ML, Cloos J, et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood. 2010;116:1747\u201354.","journal-title":"Blood"},{"key":"441_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693\u2013705.","journal-title":"Cell"},{"key":"441_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1139\/o05-041","volume":"83","author":"L Verdone","year":"2005","unstructured":"Verdone L, Caserta M, Di Mauro E. Role of histone acetylation in the control of gene expression. Biochem Cell Biol. 2005;83:344\u201353.","journal-title":"Biochem Cell Biol"},{"key":"441_CR31","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1001\/jama.2010.1862","volume":"304","author":"AJ Gentles","year":"2010","unstructured":"Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. J Am Med Assoc. 2010;304:2706\u201315.","journal-title":"J Am Med Assoc"},{"key":"441_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433\u20137.","journal-title":"Nature"},{"key":"441_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.ai.2017.12.003","volume":"137","author":"RA Backer","year":"2018","unstructured":"Backer RA, Hombrink P, Helbig C, Amsen D. The fate choice between effector and memory T cell lineages: asymmetry, signal integration, and feedback to create bistability. Adv Immunol. 2018;137:43\u201382.","journal-title":"Adv Immunol"},{"key":"441_CR34","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.4049\/jimmunol.1700247","volume":"199","author":"D Sorcini","year":"2017","unstructured":"Sorcini D, Bruscoli S, Frammartino T, Cimino M, Mazzon E, Galuppo M, et al. Wnt\/\u03b2-catenin signaling induces integrin \u03b14\u03b21 in T cells and promotes a progressive neuroinflammatory disease in mice. J Immunol. 2017;199:3031\u201341.","journal-title":"J Immunol"},{"key":"441_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.leukres.2015.04.007","volume":"39","author":"S Galli","year":"2015","unstructured":"Galli S, Zlobec I, Schurch C, Perren A, Ochsenbein AF, Banz Y. CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis. Leuk Res. 2015;39:749\u201356.","journal-title":"Leuk Res"},{"key":"441_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s12094-016-1489-x","volume":"18","author":"F Kong","year":"2016","unstructured":"Kong F, Gao F, Li H, Liu H, Zhang Y, Zheng R, et al. CD47: a potential immunotherapy target for eliminating cancer cells. Clin Transl Oncol. 2016;18:1051\u20135.","journal-title":"Clin Transl Oncol"},{"key":"441_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2016.01.008","volume":"164","author":"SL McArdel","year":"2016","unstructured":"McArdel SL, Terhorst C, Sharpe AH. Roles of CD48 in regulating immunity and tolerance. Clin Immunol. 2016;164:10\u201320.","journal-title":"Clin Immunol"},{"key":"441_CR38","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/ijc.29296","volume":"136","author":"B Seubert","year":"2015","unstructured":"Seubert B, Cui H, Simonavicius N, Honert K, Schafer S, Reuning U, et al. Tetraspanin CD63 acts as a pro-metastatic factor via beta-catenin stabilization. Int J Cancer. 2015;136:2304\u201315.","journal-title":"Int J Cancer"},{"key":"441_CR39","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.4049\/jimmunol.179.10.7128","volume":"179","author":"Y Yamaguchi","year":"2007","unstructured":"Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol. 2007;179:7128\u201336.","journal-title":"J Immunol"},{"key":"441_CR40","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121:2350\u201360.","journal-title":"J Clin Invest"},{"key":"441_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.immuni.2015.08.014","volume":"43","author":"D Gorenshteyn","year":"2015","unstructured":"Gorenshteyn D, Zaslavsky E, Fribourg M, Park CY, Wong AK, Tadych A, et al. Interactive big data resource to elucidate human immune pathways and diseases. Immunity. 2015;43:605\u201314.","journal-title":"Immunity"},{"key":"441_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306.","journal-title":"Nat Rev Cancer"},{"key":"441_CR43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","volume":"61","author":"RR Ji","year":"2012","unstructured":"Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61:1019\u201331.","journal-title":"Cancer Immunol Immunother"},{"key":"441_CR44","first-page":"51","volume":"7","author":"F Rosa Di","year":"2016","unstructured":"Di Rosa F, Gebhardt T. Bone marrow T cells and the integrated functions of recirculating and tissue-resident memory T cells. Front Immunol. 2016;7:51","journal-title":"Front Immunol"},{"key":"441_CR45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.18632\/genesandcancer.65","volume":"6","author":"L Haery","year":"2015","unstructured":"Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer. 2015;6:184\u2013213.","journal-title":"Genes Cancer"},{"key":"441_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/ni.3456","volume":"17","author":"S Xing","year":"2016","unstructured":"Xing S, Li F, Zeng Z, Zhao Y, Yu S, Shan Q, et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity. Nat Immunol. 2016;17:695\u2013703.","journal-title":"Nat Immunol"},{"issue":"9","key":"441_CR47","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","volume":"32","author":"Jooeun Bae","year":"2018","unstructured":"Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018;32:1932\u201347.","journal-title":"Leukemia"},{"key":"441_CR48","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","volume":"116","author":"O Goodyear","year":"2010","unstructured":"Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116:1908\u201318.","journal-title":"Blood"},{"issue":"374","key":"441_CR49","doi-asserted-by":"publisher","first-page":"eaaj2025","DOI":"10.1126\/scitranslmed.aaj2025","volume":"9","author":"Stephen S. Chung","year":"2017","unstructured":"Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci Transl Med. 2017;9:eaaj2025.","journal-title":"Science Translational Medicine"},{"key":"441_CR50","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","volume":"123","author":"E Nievergall","year":"2014","unstructured":"Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, et al. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123:1218\u201328.","journal-title":"Blood"},{"key":"441_CR51","first-page":"329","volume":"4","author":"N Onetto-Pothier","year":"1990","unstructured":"Onetto-Pothier N, Aumont N, Haman A, Park L, Clark SC, De Lean A, et al. IL-3 inhibits the binding of GM-CSF to AML blasts, but the two cytokines act synergistically in supporting blast proliferation. Leukemia. 1990;4:329\u201336.","journal-title":"Leukemia"},{"key":"441_CR52","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","volume":"100","author":"U Testa","year":"2002","unstructured":"Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980\u20138.","journal-title":"Blood"},{"key":"441_CR53","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","volume":"114","author":"R Dieu Le","year":"2009","unstructured":"Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114:3909\u201316.","journal-title":"Blood"},{"key":"441_CR54","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0301-472X(01)00636-1","volume":"29","author":"M Narita","year":"2001","unstructured":"Narita M, Takahashi M, Liu A, Nikkuni K, Furukawa T, Toba K, et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol. 2001;29:709\u201319.","journal-title":"Exp Hematol"},{"key":"441_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nri1529","volume":"5","author":"FJ Staal","year":"2005","unstructured":"Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT\u2013WNT situation. Nat Rev Immunol. 2005;5:21\u201330.","journal-title":"Nat Rev Immunol"},{"key":"441_CR56","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","volume":"327","author":"Y Wang","year":"2010","unstructured":"Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327:1650\u20133.","journal-title":"Science"},{"key":"441_CR57","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccr.2010.10.032","volume":"18","author":"J Yeung","year":"2010","unstructured":"Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, et al. \u03b2-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18:606\u201318.","journal-title":"Cancer Cell"},{"key":"441_CR58","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2003-09-3335","volume":"103","author":"X Zheng","year":"2004","unstructured":"Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, et al. Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells. Blood. 2004;103:3535\u201343.","journal-title":"Blood"},{"key":"441_CR59","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1365-2141.2007.06914.x","volume":"140","author":"J Xu","year":"2008","unstructured":"Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M, et al. Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2008;140:394\u2013401.","journal-title":"Br J Haematol"},{"key":"441_CR60","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.leu.2404239","volume":"20","author":"L Ysebaert","year":"2006","unstructured":"Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006;20:1211\u20136.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0441-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:37:13Z","timestamp":1684618633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0441-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0441-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"15 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}